Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

MBX

MBX Biosciences Inc.

Sep 20 • 01:29PM ET

23.15

Dollar change +1.92
Percentage change 9.04	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Financials • Options • Save to Portfolio • Create Alert

Index	-	P/E	-	EPS (ttm)	-	Insider Own	53.70%	Shs Outstand	31.85M	Perf Week	-2.11%
Market Cap	737.33M	Forward P/E	-	EPS next Y	-	Insider Trans	98.80%	Shs Float	14.75M	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	-3.07	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf Year	-
Cash/sh	1.74	P/C	13.34	EPS next 5Y	-	ROE	-	52W Range	20.29 - 26.08	Perf YTD	-2.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-11.23%	Beta	-
Dividend TTM	-	Quick Ratio	7.17	Sales past 5Y	0.00%	Gross Margin	-	52W Low	14.12%	ATR (14)	2.78
Dividend Ex-Date	-	Current Ratio	7.17	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	- -
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.75	Prev Close	21.23
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	469.70K	Price	23.15
SMA20	6.16%	SMA50	6.16%	SMA200	6.16%	Trades		Volume	221,724	Change	9.04%

Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mathers Edward T	Director	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:28 PM
BASKETT FOREST	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:26 PM
Behbahani Ali	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:24 PM
Chang Carmen	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:23 PM
Florence Anthony A. Jr.	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:21 PM
Makhzoumi Mohamad	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:20 PM
Walker Paul Edward	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:18 PM
Yang Rick	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:17 PM
SANDELL SCOTT D	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:14 PM
ORBIMED ADVISORS LLC	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	3,158,428	Sep 17 08:13 PM
New Enterprise Associates 17,	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:12 PM
Frazier Life Sciences X, L.P.	10% Owner	Sep 16 '24	Buy	16.00	625,000	10,000,000	4,552,774	Sep 17 08:11 PM
Heron Patrick J	Director	Sep 16 '24	Buy	16.00	625,000	10,000,000	4,552,774	Sep 17 08:09 PM
Aynechi Tiba	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	2,136,335	Sep 17 08:05 PM
GORDON CARL L	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	3,158,428	Sep 17 08:05 PM

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

Sep 20 • 01:29PM ET

38.82

Dollar change -0.53
Percentage change -1.35	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

MIRM Mirum Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.34	Insider Own	20.47%	Shs Outstand	46.72M	Perf Week	-5.59%
Market Cap	1.85B	Forward P/E	-	EPS next Y	-0.81	Insider Trans	-0.39%	Shs Float	37.94M	Perf Month	-5.87%
Income	-106.65M	PEG	-	EPS next Q	-0.43	Inst Own	95.91%	Short Float	18.77%	Perf Quarter	21.12%
Sales	264.38M	P/S	7.01	EPS this Y	55.09%	Inst Trans	11.22%	Short Ratio	10.88	Perf Half Y	49.08%
Book/sh	4.81	P/B	8.06	EPS next Y	54.33%	ROA	-19.32%	Short Interest	7.12M	Perf Year	24.90%
Cash/sh	5.83	P/C	6.65	EPS next 5Y	-	ROE	-69.35%	52W Range	23.14 - 45.23	Perf YTD	31.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.57%	ROI	-19.59%	52W High	-14.17%	Beta	1.15
Dividend TTM	-	Quick Ratio	3.09	Sales past 5Y	88.90%	Gross Margin	73.04%	52W Low	67.76%	ATR (14)	1.72
Dividend Ex-Date	-	Current Ratio	3.28	EPS Y/Y TTM	50.67%	Oper. Margin	-40.07%	RSI (14)	42.15	Volatility	4.40% 4.10%
Employees	264	Debt/Eq	1.38	Sales Y/Y TTM	128.34%	Profit Margin	-40.34%	Recom	1.09	Target Price	59.27
Option/Short	Yes / Yes	LT Debt/Eq	1.38	EPS Q/Q	73.15%	Payout	-	Rel Volume	0.42	Prev Close	39.35
Sales Surprise	3.79%	EPS Surprise	-10.10%	Sales Q/Q	107.68%	Earnings	Aug 07 AMC	Avg Volume	654.91K	Price	38.82
SMA20	-6.37%	SMA50	-4.67%	SMA200	24.98%	Trades		Volume	174,021	Change	-1.35%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Citigroup	Buy	$21

Show Previous Ratings

Sep-10-24 08:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
11:31AM	Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-24 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-19-24 11:06AM	Mirum (MIRM) Banks on Livmarli, Overdependence a Concern (Zacks)
07:00PM	Loading…
Aug-09-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.79%
Aug-08-24 11:01AM	Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top (Zacks)
Aug-07-24 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-31-24 04:30PM	Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024 (Business Wire)
Jul-29-24 07:28AM	Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains? (Zacks)
Jul-25-24 08:30AM	Mirums LIVMARLI Now Approved for PFIC in Patients 12 Months and Older (Business Wire)
Jul-12-24 01:22PM	Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves (Investor's Business Daily)
Jul-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-24 10:37AM	Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion (Zacks)
11:38AM	Loading…
Jul-08-24 11:38AM	Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why (Zacks)
08:30AM	Mirum Pharmaceuticals LIVMARLI Approved in the European Union for Patients with PFIC (Business Wire)
Jun-28-24 02:26PM	MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50 (Investor's Business Daily)
08:30AM	Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX (Business Wire)
Jun-25-24 11:31AM	Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling (Investor's Business Daily)
Jun-18-24 11:14AM	Mirum (MIRM) Soars on Interim Data From Liver Disease Studies (Zacks) -11.36%
05:46AM	Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-17-24 08:00AM	Mirums Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies (Business Wire) +27.31%
Jun-16-24 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 (Business Wire)
Jun-10-24 10:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-07-24 11:30AM	Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report? (Zacks)
Jun-06-24 09:30AM	Long-Term Data from Mirums LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress (Business Wire) -5.10%
Jun-05-24 04:05PM	Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
Jun-03-24 06:46AM	EMA CHMP endorses Mirum Pharmaceuticals LIVMARLI for PFIC (Pharmaceutical Technology) +5.49%
May-31-24 08:30AM	Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older (Business Wire)
08:30AM	Loading…
May-29-24 08:30AM	Long-Term Data from Mirums LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress (Business Wire)
May-28-24 10:02AM	Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns (Zacks)
May-18-24 07:00AM	Mirum Pharmaceuticals LIVMARLI Data Showcased at ESPGHAN Annual Meeting (Business Wire)
May-13-24 09:40AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
01:55PM	Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss (GuruFocus.com)
01:12PM	Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating (MT Newswires)
May-09-24 11:46AM	Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
07:40AM	Q1 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:49AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ... (GuruFocus.com)
May-08-24 04:02PM	Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:10PM	Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:30AM	Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC (Business Wire)
May-02-24 02:33PM	Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management (Newsfile)
May-01-24 04:10PM	Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 (Business Wire)
Apr-25-24 10:02AM	Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-10-24 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 08:30AM	Mirum Pharmaceuticals LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canadas CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome (Business Wire)
Mar-29-24 11:30AM	Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-25-24 11:46PM	Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares (GuruFocus.com)
07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire)
Mar-15-24 09:32AM	Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use (Zacks)
Mar-13-24 06:00PM	Mirum Pharmaceuticals LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (Business Wire)
Mar-08-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-24 08:00AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Feb-29-24 11:34AM	Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat (Zacks)
09:49AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:30AM	Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirums LIVMARLI (Business Wire)
Feb-28-24 05:35PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:38PM	Mirum Pharmaceuticals Inc (MIRM) Reports Robust Revenue Growth and Expanding Commercial ... (GuruFocus.com)
04:03PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update (Business Wire)
Feb-21-24 04:05PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024 (Business Wire)
Feb-09-24 09:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.97%
Feb-05-24 07:00AM	NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer (GlobeNewswire)
Jan-23-24 11:44AM	Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback (Zacks)
Jan-19-24 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-16-24 08:30AM	Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer (Business Wire)
Jan-15-24 04:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.91%
Jan-08-24 08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates (Business Wire)
Jan-03-24 08:45AM	Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-23 01:05PM	United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall, Monday, 12/18/2023 (Associated Press Finance) -15.87%
08:37AM	Mirum Pharma's liver disease therapy fails in mid-stage study (Reuters)
08:30AM	Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia (Business Wire)
Dec-08-23 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-30-23 09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile)
Nov-20-23 04:05PM	Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 02:00PM	Mirum Pharmaceuticals Presents New Data at The Liver Meeting (Business Wire) +6.57%
Nov-10-23 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-23 09:10AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 08:30AM	Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference (Business Wire) +5.67%
Nov-02-23 07:13PM	Mirum Pharmaceuticals Inc (MIRM) Reports Q3 2023 Revenue of $47.7 Million, Up 154% YoY (GuruFocus.com)
04:05PM	Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Oct-30-23 10:00AM	NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:30AM	Mirum Pharmaceuticals to Present New Data at The Liver Meeting (Business Wire)
Oct-27-23 08:45AM	Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 (Business Wire)
Oct-17-23 04:30PM	Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (Business Wire)
Oct-11-23 04:52PM	7 Small-Cap Stocks That Get the Nod from Wall Street (InvestorPlace) -5.79%
Oct-10-23 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-07-23 05:00PM	Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN (Business Wire)
Oct-02-23 08:30AM	Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis (Business Wire) -7.28%
Sep-26-23 08:30AM	Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting (Business Wire)
Sep-21-23 08:30AM	Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference (Business Wire)
Sep-15-23 03:05PM	Director Michael Grey Sells 14,608 Shares of Mirum Pharmaceuticals Inc (MIRM) (GuruFocus.com)
08:30AM	Mirum Pharmaceuticals Merits a Healthy Endorsement Based on Its Charts (TheStreet.com)
06:01AM	Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength? (Zacks)
Sep-14-23 01:15PM	Director Patrick Heron Buys 8,437 Shares of Mirum Pharmaceuticals Inc (GuruFocus.com) +8.01%
Sep-13-23 01:01PM	Insider Buying: CFO Eric Bjerkholt Acquires 10,000 Shares of Mirum Pharmaceuticals Inc (GuruFocus.com)
Sep-11-23 10:07AM	Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer (Business Wire)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heron Patrick J	Director	Sep 06 '24	Buy	41.58	230	9,563	162,193	Sep 10 05:04 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jul 23 '24	Option Exercise	2.94	34,013	99,862	126,783	Jul 24 05:32 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '24	Sale	34.00	375	12,750	2,426	Jul 03 06:19 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Jun 24 '24	Option Exercise	2.94	30,559	89,721	57,965	Jun 25 05:15 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Jun 24 '24	Sale	34.00	30,559	1,039,006	27,406	Jun 25 05:15 PM
Ramasastry Saira	Director	Jun 05 '24	Option Exercise	14.12	5,000	70,600	5,000	Jun 07 06:20 PM
Ramasastry Saira	Director	Jun 05 '24	Sale	25.68	5,000	128,400	0	Jun 07 06:20 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 27 '24	Buy	24.80	2,000	49,600	14,000	Mar 27 08:47 PM
Radovich Peter	PRESIDENT AND COO	Mar 25 '24	Sale	25.80	4,303	111,017	29,013	Mar 25 05:41 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 18 '24	Buy	25.80	2,000	51,600	12,000	Mar 18 05:34 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Feb 02 '24	Sale	26.19	1,214	31,797	28,691	Feb 05 09:12 PM
Longpre Lara	CHIEF DEVELOPMENT OFFICER	Feb 02 '24	Sale	26.19	847	22,184	104,407	Feb 05 09:10 PM
Radovich Peter	PRESIDENT AND COO	Feb 02 '24	Sale	26.19	1,790	46,883	34,695	Feb 05 09:05 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '24	Sale	26.19	6,013	157,491	104,112	Feb 05 09:04 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '24	Sale	26.19	735	19,251	1,759	Feb 02 09:28 PM
Radovich Peter	CHIEF OPERATING OFFICER	Jan 08 '24	Sale	28.03	1,408	39,473	36,485	Jan 09 08:28 PM
Longpre Lara	CHIEF DEVELOPMENT OFFICER	Jan 08 '24	Sale	28.04	1,019	28,568	105,254	Jan 09 08:25 PM
Vig Pamela	HEAD OF RESEARCH & DEVELOPMENT	Jan 08 '24	Sale	28.03	1,408	39,472	29,905	Jan 09 08:21 PM
Peetz Christopher	PRESIDENT AND CEO	Jan 08 '24	Sale	28.03	5,209	146,033	110,125	Jan 09 08:12 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 08 '24	Sale	28.04	528	14,803	722	Jan 09 08:09 PM
Howe Jolanda	SVP, Global Controller	Dec 05 '23	Option Exercise	2.94	2,500	7,350	2,500	Dec 06 05:16 PM
Howe Jolanda	SVP, Global Controller	Dec 05 '23	Sale	32.40	2,500	81,000	0	Dec 06 05:16 PM

Open in Screener

ARQT

Arcutis Biotherapeutics Inc

Sep 20 • 01:29PM ET

9.92

Dollar change -0.22
Percentage change -2.17	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

ARQT Arcutis Biotherapeutics Inc daily Stock Chart

Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-2.18	Insider Own	13.25%	Shs Outstand	116.89M	Perf Week	-6.94%
Market Cap	1.16B	Forward P/E	-	EPS next Y	-1.15	Insider Trans	-1.21%	Shs Float	101.40M	Perf Month	18.94%
Income	-198.76M	PEG	-	EPS next Q	-0.41	Inst Own	99.47%	Short Float	24.34%	Perf Quarter	16.84%
Sales	132.06M	P/S	8.78	EPS this Y	59.98%	Inst Trans	9.65%	Short Ratio	10.10	Perf Half Y	-2.55%
Book/sh	1.60	P/B	6.20	EPS next Y	24.08%	ROA	-51.93%	Short Interest	24.68M	Perf Year	68.71%
Cash/sh	3.11	P/C	3.19	EPS next 5Y	9.80%	ROE	-148.92%	52W Range	1.76 - 13.17	Perf YTD	207.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-48.07%	ROI	-50.55%	52W High	-24.68%	Beta	1.18
Dividend TTM	-	Quick Ratio	8.19	Sales past 5Y	303.42%	Gross Margin	92.01%	52W Low	463.64%	ATR (14)	0.73
Dividend Ex-Date	-	Current Ratio	8.46	EPS Y/Y TTM	60.54%	Oper. Margin	-136.13%	RSI (14)	46.72	Volatility	7.64% 7.33%
Employees	296	Debt/Eq	1.11	Sales Y/Y TTM	1032.90%	Profit Margin	-150.51%	Recom	1.29	Target Price	18.57
Option/Short	Yes / Yes	LT Debt/Eq	1.11	EPS Q/Q	63.33%	Payout	-	Rel Volume	1.01	Prev Close	10.14
Sales Surprise	6.08%	EPS Surprise	18.68%	Sales Q/Q	494.57%	Earnings	Aug 14 AMC	Avg Volume	2.44M	Price	9.92
SMA20	-4.79%	SMA50	0.01%	SMA200	21.10%	Trades		Volume	1,561,901	Change	-2.17%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-03-24	Upgrade	Mizuho	Neutral → Buy	$4 → $8
Oct-26-23	Downgrade	Mizuho	Buy → Neutral	$57 → $4
Oct-13-23	Downgrade	Goldman	Buy → Neutral	$32 → $6
Sep-07-22	Initiated	Needham	Buy	$46
Mar-17-22	Initiated	Goldman	Buy	$45
Jun-30-21	Initiated	Mizuho	Buy	$58
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$52
Nov-09-20	Upgrade	Goldman	Neutral → Buy	$34 → $36
Oct-08-20	Initiated	Truist	Buy	$38
Feb-25-20	Initiated	Guggenheim	Buy	$36
Feb-25-20	Initiated	Goldman	Neutral	$30
Feb-25-20	Initiated	Cowen	Outperform	$55
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

Sep-19-24 08:00AM	Arcutis Announces Publication of ZORYVE (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology (GlobeNewswire)
Sep-06-24 01:29AM	Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) (GuruFocus.com)
Sep-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255 (GlobeNewswire)
12:01AM	Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
05:22PM	Loading…
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-28-24 08:00AM	Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis (GlobeNewswire)
Aug-22-24 08:00AM	Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-24 01:15PM	Q2 2024 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -11.27%
Aug-14-24 09:00PM	CORRECTION Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-24 10:00AM	Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know (Zacks)
Aug-02-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-01-24 04:00PM	Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 (GlobeNewswire) -5.86%
07:35AM	Loading…
Jul-29-24 07:35AM	Arcutis Announces ZORYVE U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc. (GlobeNewswire)
07:30AM	Arcutis Launches ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis (GlobeNewswire)
Jul-23-24 02:57PM	7 Biotech Stocks to Keep on Your Clinical Radar (InvestorPlace)
08:00AM	Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over (GlobeNewswire)
Jul-22-24 08:00AM	Arcutis to Host ZORYVE (Roflumilast) Cream 0.15% FDA Approval Call With KOL (GlobeNewswire)
Jul-19-24 09:40AM	Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-17-24 09:54AM	Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why (Zacks)
Jul-10-24 01:13PM	Arcutis bags FDA approval for atopic dermatitis cream after delay (Pharmaceutical Technology)
11:23AM	FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years (Benzinga)
07:48AM	AbbVie names new R&D head; Arcutis eczema cream approved (BioPharma Dive)
Jul-09-24 04:53PM	FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age (GlobeNewswire)
08:00AM	Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis (GlobeNewswire)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-03-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.27%
Jul-02-24 07:45AM	Cheap Stocks To Buy: This Microcap Gold Stock Breaks Out (Investor's Business Daily)
09:40AM	Loading…
Jun-17-24 09:40AM	Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? (Zacks) -7.76%
Jun-14-24 09:55AM	Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet (Zacks) -7.60%
Jun-13-24 06:00AM	Have $5-10? 7 Affordable Stocks That Are About to Breakout. (InvestorPlace) +15.31%
Jun-10-24 02:30PM	Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference (GlobeNewswire)
Jun-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference (GlobeNewswire)
Jun-03-24 08:00AM	Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-31-24 09:40AM	Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? (Zacks)
May-20-24 09:55AM	Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 101.09%: Here's is How to Trade (Zacks)
May-16-24 11:23AM	Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise (MT Newswires)
May-15-24 12:54PM	Q1 2024 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +13.65%
12:03PM	Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating (MT Newswires)
09:12AM	Sector Update: Health Care Stocks Rise Pre-Bell Wednesday (MT Newswires)
08:53AM	Sector Update: Health Care (MT Newswires)
08:46AM	Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating (MT Newswires)
08:19AM	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
04:24AM	Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket (MT Newswires)
03:13AM	Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
May-14-24 08:57PM	ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:53PM	Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump (MT Newswires)
04:00PM	Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Expert Panel Review Further Validates Use of ZORYVE (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology (GlobeNewswire)
May-03-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.98%
Apr-29-24 04:00PM	Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire) -5.24%
Apr-10-24 08:00AM	Arcutis Appoints David Topper as Chief Financial Officer (GlobeNewswire)
Apr-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.49% +10.49%
Apr-01-24 07:00AM	Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream (GlobeNewswire)
Mar-28-24 08:00AM	Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-19-24 09:55AM	Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-18-24 09:55AM	Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? (Zacks)
Mar-11-24 08:00AM	Arcutis Promotes Todd Tucker to Chief Human Resources Officer (GlobeNewswire) -9.96%
Mar-10-24 04:00PM	Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-09-24 04:00PM	New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction (GlobeNewswire)
Mar-08-24 07:33PM	Peabody Energy, Citi Trends, and More Stocks See Action From Activist Investors (Barrons.com) +7.42% -9.96%
Mar-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-24 04:00PM	Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -6.97%
08:00AM	Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-01-24 09:55AM	Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? (Zacks) +14.49%
09:40AM	Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-29-24 05:00PM	Arcutis to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
11:33AM	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 11:30PM	Arcutis Announces Pricing of $150 Million Public Offering (GlobeNewswire)
04:10PM	Arcutis Announces Proposed Public Offering (GlobeNewswire)
04:00PM	Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan (GlobeNewswire)
12:16AM	Q4 2023 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 08:11AM	Arcutis Biotherapeutics Inc (ARQT) Reports Significant Revenue Growth in Q4 2023 (GuruFocus.com) +9.70%
05:50AM	Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-16-24 08:00AM	Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +16.69%
Feb-06-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.32%
Feb-01-24 03:04PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Arcutis Biotherapeutics Inc (GuruFocus.com) +13.12%
Jan-31-24 08:00AM	Arcutis to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 08:00AM	Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial (GlobeNewswire) +14.34%
Jan-22-24 08:00AM	ZORYVE (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States (GlobeNewswire) +8.92%
Jan-18-24 12:00PM	Arcutis Biotherapeutics, Inc. (ARQT) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
Jan-14-24 04:00AM	ZORYVE (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids (GlobeNewswire)
04:00AM	Majority of Individuals with Atopic Dermatitis Improved with Arcutis' Roflumilast Cream 0.15% According to New Data from Phase 3 Program (GlobeNewswire)
Dec-23-23 07:32PM	11 High Growth Micro-Cap Stocks to Buy (Insider Monkey)
Dec-19-23 11:48AM	Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis (Zacks)
Dec-18-23 06:02AM	Arcutis Biotherapeutics receives FDA approval for ZORYVE to treat seborrheic dermatitis (Pharmaceutical Business Review)
04:58AM	Arcutis shares jump after FDA approves drug for chronic skin condition (Investing.com)
Dec-15-23 05:19PM	UPDATE 3-US FDA approves Arcutis' drug to treat chronic skin disease (Reuters)
05:14PM	US FDA approves Arcutis' drug to treat chronic skin disease (Reuters)
05:11PM	FDA Approves Arcutis' ZORYVE (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older (GlobeNewswire)
Dec-01-23 10:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.15% +12.56%
Nov-29-23 08:00AM	FDA Accepts Arcutis' Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6 (GlobeNewswire) -6.86%
Nov-17-23 09:35AM	After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT) (Zacks)
Nov-16-23 11:04PM	Polar Capital Holdings Plc Bolsters Portfolio with Arcutis Biotherapeutics Inc Stake (GuruFocus.com) -6.25%
Nov-15-23 01:26PM	3 Biotech Stocks With Key Catalysts Coming in December (InvestorPlace)
Nov-14-23 05:04PM	FMR LLC Reduces Stake in Arcutis Biotherapeutics Inc (GuruFocus.com)

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Welgus Howard G.	Director	Sep 03 '24	Sale	10.77	10,000	107,695	191,944	Sep 05 05:56 PM
Welgus Howard G.	Director	Sep 03 '24	Proposed Sale	10.77	10,000	107,695		Sep 03 01:37 PM
Burnett Patrick	See Remarks	Aug 19 '24	Sale	8.29	1,728	14,318	194,859	Aug 21 04:39 PM
Burnett Patrick	Officer	Aug 19 '24	Proposed Sale	8.29	1,728	14,318		Aug 19 05:43 PM
Matsuda Masaru	See Remarks	Aug 02 '24	Sale	9.02	5,220	47,064	183,288	Aug 05 04:37 PM
Burnett Patrick	See Remarks	Aug 02 '24	Sale	9.02	13,206	119,106	196,587	Aug 05 04:37 PM
Watanabe Todd Franklin	See Remarks	Aug 02 '24	Sale	9.02	14,487	130,648	846,263	Aug 05 04:37 PM
Welgus Howard G.	Director	Aug 01 '24	Option Exercise	1.68	6,614	11,115	186,953	Aug 05 04:37 PM
Welgus Howard G.	Director	Aug 01 '24	Sale	9.87	10,000	98,696	176,953	Aug 05 04:37 PM
Matsuda Masaru	Officer	Aug 02 '24	Proposed Sale	9.02	5,220	47,063		Aug 02 04:22 PM
Burnett Patrick	Officer	Aug 01 '24	Proposed Sale	9.14	13,026	119,105		Aug 02 04:20 PM
Watanabe Todd Franklin	Officer	Aug 02 '24	Proposed Sale	9.02	14,487	130,648		Aug 02 04:19 PM
Welgus Howard G.	Director	Aug 01 '24	Proposed Sale	9.87	10,000	98,696		Aug 01 04:45 PM
Welgus Howard G.	Director	Jul 01 '24	Option Exercise	1.68	10,000	16,806	190,339	Jul 02 07:13 PM
Welgus Howard G.	Director	Jul 01 '24	Sale	9.31	10,000	93,141	180,339	Jul 02 07:13 PM
Welgus Howard G.	Director	Jun 04 '24	Option Exercise	1.68	10,000	16,806	180,200	Jun 06 04:15 PM
Welgus Howard G.	Director	Jun 04 '24	Sale	8.01	10,000	80,092	170,200	Jun 06 04:15 PM
Burnett Patrick	See Remarks	May 30 '24	Option Exercise	0.00	23,000	0	232,793	May 31 04:50 PM
Burnett Patrick	See Remarks	May 29 '24	Sale	8.72	49,952	435,387	209,793	May 31 04:50 PM
Burnett Patrick	See Remarks	May 30 '24	Sale	8.75	23,000	201,319	209,793	May 31 04:50 PM
Matsuda Masaru	See Remark	May 28 '24	Sale	9.01	1,775	15,988	188,508	May 29 07:38 PM
Edwards Larry Todd	SVP Chief Commercial Officer	May 17 '24	Sale	8.98	7,640	68,582	140,360	May 20 05:12 PM
Moore Matthew Richard	SVP and Chief Business Officer	May 02 '24	Sale	8.74	4,681	40,902	145,505	May 03 04:29 PM
Watanabe Todd Franklin	See Remarks	May 02 '24	Sale	8.74	13,783	120,433	860,750	May 03 04:22 PM
Matsuda Masaru	See Remark	May 02 '24	Sale	8.74	5,016	43,829	185,408	May 03 04:22 PM
Burnett Patrick	See Remarks	May 02 '24	Sale	8.74	9,555	83,490	259,745	May 03 04:22 PM
Matsuda Masaru	See Remark	Mar 04 '24	Sale	11.12	3,760	41,816	190,424	Mar 06 05:14 PM
Burnett Patrick	See Remarks	Mar 04 '24	Sale	11.12	4,782	53,182	269,300	Mar 06 05:12 PM
Watanabe Todd Franklin	See Remarks	Mar 04 '24	Sale	11.12	14,903	165,739	874,533	Mar 06 05:09 PM
Moore Matthew Richard	SVP and Chief Business Officer	Mar 04 '24	Sale	11.12	3,468	38,568	146,020	Mar 06 05:08 PM
Heron Patrick J	Director	Mar 04 '24	Buy	9.50	21,052	199,994	8,785,284	Mar 06 04:28 PM
Watanabe Todd Franklin	See Remarks	Feb 28 '24	Sale	10.60	2,465	26,129	889,436	Mar 01 04:11 PM
Burnett Patrick	See Remarks	Jan 02 '24	Sale	3.54	1,325	4,692	57,032	Jan 03 05:30 PM
Watanabe Todd Franklin	See Remarks	Dec 01 '23	Option Exercise	1.68	59,525	100,038	513,682	Dec 01 08:51 PM
Matsuda Masaru	See Remark	Nov 21 '23	Sale	1.98	1,850	3,661	46,634	Nov 21 05:47 PM
Frazier Life Sciences VIII, L.	10% Owner	Oct 24 '23	Buy	2.50	80,000	200,000	8,764,232	Oct 26 04:09 PM

MBX

MBX Biosciences Inc.

MIRM

Mirum Pharmaceuticals Inc

ARQT

Arcutis Biotherapeutics Inc

Upgrade your FINVIZ experience